HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma

• Status: Terminated
• Trial end date: 2015-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Phase IV, open-label, randomized, two-arm, multi-center study in patients with metastatic melanoma who are treatment naïve or have previously received a single non-immunologic therapy.

Treatment Arm 1: Patients will receive two courses (four cycles) of High Dose Interleukin-2 (HD IL-2) followed by one course (four doses) of ipilimumab.

Treatment Arm 2: Patients will receive one course (four doses) of ipilimumab followed by two courses (four cycles) of HD IL-2.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Clinigen, Inc.; Prometheus Laboratories
• Collaborators: Johns Hopkins University; M.D. Anderson Cancer Center
• Treatments: Aldesleukin; Antibodies, Monoclonal; Interleukin-2; Ipilimumab

Criteria

Inclusion Criteria:

• Male or female patients 18 years or older

• Confirmed and measurable metastatic melanoma with at least one measurable lesion for evaluation of response

• Meets the requirements for HD IL-2 therapy per Institutional guidelines

• Meets the requirements for ipilimumab therapy per Institutional guidelines

• Treatment naïve or has received only one systemic therapy apart from adjuvant therapy.

• At least 4 weeks since last adjuvant therapy or other cancer treatment

• Willing and able to give informed consent and participate in study procedures as described in the 12PLK02 and 10PLK13 protocols. Patients consented for 12PLK02 will also be asked to participate in the 10PLK13 PROCLAIM registry study.

Exclusion Criteria:

• Patients with known or suspected infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV) or other infectious hepatitis

• Pregnant, nursing or planning to become pregnant

• Untreated brain metastases. (Brain metastases that have been treated, which no longer require corticosteroid therapy and are without progression by MRI at least 6 weeks after definitive therapy are acceptable.)

• Received prior ipilimumab therapy (Prior Adjuvant Ipilimumab and Adjuvant Interferon are permitted with a minimum 4 week washout)

• Received prior HD IL-2 therapy.

• Received investigational drug within 30 days prior to study dosing. Patients may participate in non-interventional or observational clinical studies, including the 10PLK13 PROCLAIM registry study.

• Concomitant disease or condition that would interfere with the conduct of the study or that would, in the opinion of the Investigator, pose an unacceptable risk to the patient in this study.